Results 31 to 40 of about 8,274 (166)

Eosinophilic granulomatosis with polyangiitis following flu guard influenza vaccination: A case report

Clinical Case Reports, 2023
Key Clinical Message This case highlights a potential association between influenza vaccination and the development of eosinophilic granulomatosis with polyangiitis (EGPA), prompting the need for increased vigilance regarding vaccine‐related autoimmune ...
Mehdi Jafarpour, Sara Daneshvar, Amir Taher Eftekharsadat, Alireza Khabbazi, Omid Pourbagherian   +4 more
doaj   +1 more source

Is it atopic asthma, chronic eosinophilic pneumonia, or eosinophilic granulomatosis with polyangiitis?

Journal of Family Medicine and Primary Care, 2022
A 45-year-old man, used to work in a cement factory, presented to us with a history of adult-onset sub-optimally controlled asthma and was initially managed as a case of acute exacerbation of allergic asthma.
Tushar Vidhale, Manas Pustake, Aakash Parab, Tanmoy Roy, Sanjay Sasane, Sneha More, Charmi Gandhi, Tuhina Mishra   +7 more
doaj   +1 more source

Improving patient outcomes: Mepolizumab’s impact in IL-5-mediated diseases

Lung India
The Interleukin-5 (IL-5)-mediated pathogenic role of eosinophils in airway disorders including severe eosinophilic asthma (SEA), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), and rare hyper ...
Dipti Gothi, Raghupathi Narasimhan, Randeep Guleria, Manu Chopra, Aanchal Gvalani, Rashmi Hegde   +5 more
doaj   +1 more source

INTERLEUKIN-5 IS A NEW TARGET IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS

Научно-практическая ревматология, 2020
Interleukin-5 (IL-5) is involved in the maturation and activation of eosinophils, its production is increased in patients with eosinophilic granulomatosis with polyangiitis (EGPA).
T. V. Beketova, E. V. Arseniev
doaj   +1 more source

Unique case of mononeuritis multiplex in a patient of Eosinophilic granulomatosis with polyangiitis

Journal of Family Medicine and Primary Care
Introduction: Eosinophilic granulomatosis with polyangiitis (formerly known as Churg Strauss syndrome) is a rare multisystem autoimmune disease. It is known to affect 1-3 adults/million population worldwide.
Tattvam Shah, Param Patel, Mamta Patel
doaj   +1 more source

New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group

, 2019
The European Eosinophilic Granulomatosis with Polyangiitis (EGPA) study group first gathered in Firenze in December 2018. The discussion was centred around the clinical and therapeutic needs in EGPA which still remain unmet.
Vaglio A., Egan A., Arndt F., Mahrhold J., Prisco D., Sinico R. A., Kernder A., Troilo A., Hellmich B., Tervaert J. W. C., Urban M. L., Venhoff N., Terrier B., Kahn J. -E., Marvisi C., Jayne D., Salvarani C., Mahr A., Emmi G., Neumann T., Schiavon F., Maria Letizia Urban, Jayne, David, Venhoff, Nils, Vaglio, Augusto, Troilo, Arianna, Prisco, Domenico, Marvisi, Chiara, Urban, Maria Letizia, Sinico, Renato Alberto, Emmi, Giacomo, Salvarani, Carlo, Terrier, Benjamin   +32 more
core   +1 more source

Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis

, 2023
egpa ...
Gianenrico Senna, Elena Scarpieri, Rachele Vaia, Matteo Maule, Maule, Matteo, Marco Caminati, Patrick Pinter, Vaia, Rachele, Schiappoli, Michele, Senna, Gianenrico, Scarpieri, Elena, Michele Schiappoli, Pinter, Patrick, Caminati, Marco   +13 more
core   +1 more source

Biologics Adoption in CRSwNP and the Associated Decline in Endoscopic Sinus Surgery: A Longitudinal Claims Database Study

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Biologic treatments were introduced for chronic rhinosinusitis with nasal polyps (CRSwNP) in 2019. Treatment algorithms for medically refractory CRSwNP remain open, with patients choosing among surgery, biologics, or both. Real‐world utilization of surgery and biologics remains incompletely characterized.
Stephanie Shintani Smith, Sam L. Kaefer, Harsh Duvvuru, Robert C. Kern, Brent A. Senior, Vijay R. Ramakrishnan   +5 more
wiley   +1 more source

Effective Performance of the 2022 American College of Rheumatology/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in Pediatric Patients: An ARChiVe Study

Arthritis &Rheumatology, EarlyView.
Objective To assess the 2022 American College of Rheumatology (ACR)/EULAR classification criteria for antineutrophil cytoplasmic antibody–associated vasculitis (AAV) in children with chronic small‐to‐medium vessel vasculitis. Methods A cohort of 574 patients, identified by physician's diagnosis (MD‐diagnosis) in A Registry of Childhood Vasculitis, was ...
David A. Cabral, Else S. Bosman, Nick McPhate, Simranpreet K. Mann, Kirandeep K. Toor, Kimberly A. Morishita, Raashid Luqmani, Michael W. Beresford, James Bistolarides, Sarah Campillo, Sirirat Charuvanij, Kathryn Cook, Paul Dancey, Marietta de Guzman, Samundeeswari Deepak, Barbara Eberhard, Melissa Elder, Samuel Gagne, Katie Harrison, Adam Huber, Archana Khan, Susan Kim, Marisa S. Klein‐Gitelman, Tzielan C. Lee, Suzanne C. Li, Neil Martin, Flora McErlane, L. Nandini Moorthy, Alvaro H. Orjuela, Jonathan Park, Phil Riley, Alan M. Rosenberg, Susan Shenoi, Vidya Sivaraman, Sodality Sutnga, Tamara Tanner, Stacey E. Tarvin, Marinka Twilt, Linda Wagner‐Weiner, Rae S. M. Yeung, Kelly L. Brown, for the ARChiVe Investigators Network within the PedVas Initiative   +41 more
wiley   +1 more source

Characteristics of patients with EGPA and control subjects.

, 2015
Values are given as number (percentage), mean ± SD or median (lower-upper quartile).Abbreviations: EGPA, eosinophilic granulomatosis with polyangiitis; ECP, eosinophil cationic protein; sCD40L, soluble CD40 ligand; CRP, C-reactive protein; t-PA, tissue ...
Magdalena Celińska-Lӧwenhoff (822556), Bogdan Batko (822558), Piotr Krawiec (822557), Lucyna Mastalerz (822555), Anetta Undas (277141), Witold Tłustochowicz (822559)   +5 more
core   +1 more source